Thomas Brevig

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Life engagement improvements with cariprazine in schizophrenia: a post-hoc analysis of PANSS data from short-term studies.

Life engagement improvements with cariprazine in schizophrenia: a post-hoc analysis of PANSS data from short-term studies.

Journal: The international journal of neuropsychopharmacology

Published: December 08, 2025

Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression - Psychopathology scale for patients and informants - ADDENDUM.

Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression - Psychopathology scale for patients and informants - ADDENDUM.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: November 20, 2025

Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression - Psychopathology scale for patients and informants.

Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression - Psychopathology scale for patients and informants.

Journal: European psychiatry : the journal of the Association of European Psychiatrists

Published: August 05, 2025

Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains.

Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 16, 2025

The Transdiagnostic Global Impression - Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice.

The Transdiagnostic Global Impression - Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: June 24, 2024

Treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache: a plain language summary.

Treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache: a plain language summary.

Journal: Pain management

Published: June 26, 2023

Risk factors for migraine disease progression: a narrative review for a patient-centered approach.

Risk factors for migraine disease progression: a narrative review for a patient-centered approach.

Journal: Journal of neurology

Published: May 05, 2023

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.

Journal: The journal of headache and pain

Published: June 23, 2022

Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.

Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.

Journal: Headache

Published: May 18, 2022

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.

Journal: The journal of headache and pain

Published: October 14, 2021

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine.

Journal: The journal of headache and pain

Published: October 01, 2021

Patient preference for early onset of efficacy of preventive migraine treatments.

Patient preference for early onset of efficacy of preventive migraine treatments.

Journal: Headache

Published: August 10, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026